%0 Journal Article
%T Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
%J -
%D 2019
%R https://doi.org/10.1038/s41416-019-0462-1
%X This subgroup analysis of a phase 3 study compares outcomes for eribulin versus dacarbazine in patients with leiomyosarcoma
%U https://www.nature.com/articles/s41416-019-0462-1